Clinical trial NCT03367624: Epidemiology of Post-influenza Bacterial Pneumonia Due to a Panton-Valentine Leukocidin Positive Staphylococcus Aureus
Official title: Epidemiology of Post-influenza Bacterial Pneumonia Due to a Panton-Valentine Leukocidin Positive Staphylococcus Aureus
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Influenza
Staphylococcus Aureus Pneumonia
PV Leukocidin
Keywords: influenza
Staphylococcus Aureus
Pneumonia
PV leukocidin
ICU
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2017-12-11
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients hospitalized in intensive care units for the management of influenza pneumonia infected with Panton-Valentine Leukocidin Positive Staphylococcus aureus over a retrospective period from 2009 to winter 2016-2017.

Brief summary: Secondary bacterial influenza pneumonia caused by Panton-Valentine Leukocidin Positive Staphylococcus aureus is a rare complication but with poor prognosis. This pathology seems to affect young patients (20-40 years) without any medical history. Since the influenza pandemic of 2009, this complication is more and more mentioned, sought and diagnosed. However, the literature is poor, consisting of case reports, experimental studies on murine models, and low-power studies.

The main objective is to evaluate the mortality in intensive care units of patients post-influenza bacterial pneumonia due to a Panton-Valentine Leukocidin positive Staphylococcus aureus


Eligibility criteria: Inclusion Criteria:

* Patient treated for post-influenza bacterial pneumonia due to a Panton-Valentine Leukocidin positive Staphylococcus aureus in intensive care unit

Exclusion Criteria:

* Minor patient
* Patient under protective measurement
* Absence of bacteriological and / or virological documentation

Primary outcomes:
measure: Number of dead patients
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
Secondary outcomes:
measure: Demographic data relating to age
timeFrame: Baseline
measure: Demographic data relating to sex
timeFrame: Baseline
measure: Respiratory failure
timeFrame: Baseline
measure: Demographic data relating to immunosuppression
timeFrame: Baseline
measure: risk factors for methicillin-resistant Staphylococcus aureus
timeFrame: Baseline
measure: risk factors for methicillin-resistant Staphylococcus aureus
timeFrame: Baseline
measure: risk factors for methicillin-resistant Staphylococcus aureus
timeFrame: Baseline
measure: risk factors for methicillin-resistant Staphylococcus aureus
timeFrame: Baseline
measure: Clinical data relating to pre-admission antibiotics
timeFrame: Baseline
measure: Clinical data in the initial phase relating to SAPS 2 score
timeFrame: Baseline
measure: Clinical data in the initial phase relating to SOFA admission
timeFrame: Baseline
measure: Clinical data in the initial phase relating to neutropenia
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Clinical data in the initial phase relating to neutropenia
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Clinical data in the initial phase relating to metabolic acidosis
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Clinical data in the initial phase relating to oxygen dependence
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Clinical data in the initial phase relating to hyperthermia
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Clinical data in the initial phase relating to chills
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Clinical data in the initial phase relating to headhache
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Clinical data in the initial phase relating to productive cough
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Clinical data in the initial phase relating to dyspnoea
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Clinical data in the initial phase relating to acute respiratory failure
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Clinical data in the initial phase relating to hemoptysis
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Clinical data in the initial phase relating to uni - or multi - lobar infiltration on chest X - ray or CT scan
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Clinical data in the initial phase relating to pleural effusion
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Clinical data in the initial phase
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Clinical data in the initial phase relating to renal failure
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Prognostic factors for this pathology
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Complications
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Collection of infectious samples
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Probabilistic antibiotherapy
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Probabilistic antibiotherapy
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Prescribed antibiotic therapy
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Prescribed antibiotic therapy
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Collection of the date of introduction of adapted antibiotic therapy
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Number of patients with Influenza type A
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Number of patients with Influenza type B
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Date of initiation of anti-viral treatment in relation to the onset of symptoms and duration of anti-viral treatment
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Dosage of antiviral treatment
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
measure: Number of serious influenza infections per year and per center with early and late deaths
timeFrame: During Length of stay in intensive care unit (an average of 2 weeks)
Other outcomes:
Locations:
city: Nancy
country: France
facility: Baux
Study officials:
References: